Shengjiang Powder ameliorates myocardial injury in septic rats by downregulating the phosphorylation of P38-MAPK
- 14 Downloads
Sepsis is the systemic inflammatory response caused by infection. Cardiac dysfunction is an acknowledged result of sepsis. Shengjiang Powder, a prescribed traditional Chinese medicine, showed anti-infection and antipyretic functions in our previous study. In this study, we established a septic rat model via cecal ligation puncture (CLP) to evaluate the effects of Shengjiang Powder on sepsis and the involvement of P38 mitogen activated protein kinase (P38-MAPK) signaling. The 10 main ingredients of Shengjiang Powder were identified by LC–MS. The results of this study indicated that Shengjiang Powder at a concentration of 3.0 g/kg with SB203580 (an inhibitor of P38-MAPK) could improve myocardial injury, ameliorate the histopathological abnormalities, decrease apoptosis and upregulate proliferating cell nuclear antigen (PCNA) levels in myocardial tissues. Further, cytokine mRNA expression levels (tumor necrosis factor - alpha, TNF-α and interleukin 6, IL-6) were decreased by Shengjiang Powder and SB203580 in the myocardial tissues. Furthermore, the p-P38 protein level in myocardial tissues was upregulated in septic rats but decreased upon treatment with Shengjiang Powder and SB203580; however, the relative protein level of P38 showed no significant changes. Collectively, Shengjiang Powder showed a myocardial protective effect on rats with CLP-induced sepsis.
KeywordsCecal ligation puncture myocardial injury P38-MAPK sepsis Shengjiang Powder
This work was funded by National Natural Science Foundation of China Youth Foud (No. 81303101).
Compliance with ethical standards
Animal rights statement
All animal protocols were strictly in accordance with the international ethical guidelines and the National Institutes of Health Guide concerning the Care and Use of Laboratory Animals, and the protocols were approved by the Animal Experimentation Ethics Committee of Shanghai University of Traditional Chinese Medicine.
- Derogis PBM, Sanches LR, de Aranda VF, Colombini MP, Mangueira CLP, Katz M, Faulhaber ACL, Mendes CEA, Ferreira CEDS, França CN and Guerra JCdC 2017 Determination of rivaroxaban in patient’s plasma samples by anti-XA chromogenic test associated to high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). PLoS ONE 12 e0171272CrossRefGoogle Scholar
- Dong X 2014 Treatment of tuberculous exudative pleurisy by Jiawei Shengjiangsan decoction for 50 cases. Chin. Med. Mod. Distance Educ. China 12 28–29Google Scholar
- Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL and Young PR 1994 A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 739–746CrossRefGoogle Scholar
- Nan SL, Pan J, Zhang J, Zhao L and Fang XM 2011 Effect of Shengjiangsan on levels of IL-1β and IL-10 in serum in mouse infected by influenza virus FM1. J. Liaoning Univ. Trad. Chin. Med. 13 70–71Google Scholar
- Xia YC, Guo J and Zhou XG 2013 Clinical observation of effects of Shengjiangsan on the kidney in patients with sepsis. J. Emerg. Trad. Chin. Med. 22 214–215Google Scholar